Crinetics Pharmaceuticals/$CRNX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its products include Paltusotine and Atumelnant.
Ticker
$CRNX
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
437
ISIN
US22663K1079
Website
CRNX Metrics
BasicAdvanced
$2.9B
-
-$3.82
0.28
-
Price and volume
Market cap
$2.9B
Beta
0.28
52-week high
$59.95
52-week low
$24.10
Average daily volume
776K
Financial strength
Current ratio
22.527
Quick ratio
22.359
Long term debt to equity
3.504
Total debt to equity
4.053
Profitability
EBITDA (TTM)
-373.494
Gross margin (TTM)
-34,512.50%
Net profit margin (TTM)
-43,191.05%
Operating margin (TTM)
-49,569.74%
Management effectiveness
Return on assets (TTM)
-20.13%
Return on equity (TTM)
-30.84%
Valuation
Price to revenue (TTM)
3,451.007
Price to book
2.27
Price to tangible book (TTM)
2.27
Price to free cash flow (TTM)
-9.885
Free cash flow yield (TTM)
-10.12%
Free cash flow per share (TTM)
-308.56%
Growth
Revenue change (TTM)
-61.50%
Earnings per share change (TTM)
1.40%
3-year revenue growth (CAGR)
-43.48%
3-year earnings per share growth (CAGR)
10.38%
What the Analysts think about CRNX
Analyst ratings (Buy, Hold, Sell) for Crinetics Pharmaceuticals stock.
Bulls say / Bears say
Crinetics Pharmaceuticals has a robust cash position of $1.4 billion as of December 31, 2024, providing financial stability and the ability to fund operations into 2029. (nasdaq.com)
The company's lead product candidate, paltusotine, has an FDA Prescription Drug User Fee Act (PDUFA) target action date of September 25, 2025, for the treatment of acromegaly, indicating potential near-term revenue generation. (nasdaq.com)
Crinetics is expanding its pipeline with plans to initiate pivotal studies for atumelnant in congenital adrenal hyperplasia (CAH) and Cushing’s disease, demonstrating a commitment to addressing unmet needs in endocrine disorders. (nasdaq.com)
Crinetics reported a net loss of $298.4 million for the year ended December 31, 2024, up from $214.5 million in 2023, reflecting increased operating expenses. (nasdaq.com)
The company has no significant revenue streams, with only $1.0 million in revenues for the full year 2024, primarily from licensing agreements, indicating a reliance on future product approvals for income. (nasdaq.com)
Insider selling activity, such as the sale of 5,000 shares by insider Dana Pizzuti on February 3, 2025, may raise concerns about internal confidence in the company's near-term prospects. (americanbankingnews.com)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.
CRNX Financial Performance
Revenues and expenses
CRNX Earnings Performance
Company profitability
CRNX News
AllArticlesVideos
Crinetics Pharmaceuticals to Host R&D Day on June 26, 2025
GlobeNewsWire·4 days ago
Crinetics Pharmaceuticals Announces June 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·1 week ago
Crinetics Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference 2025
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Crinetics Pharmaceuticals stock?
Crinetics Pharmaceuticals (CRNX) has a market cap of $2.9B as of June 20, 2025.
What is the P/E ratio for Crinetics Pharmaceuticals stock?
The price to earnings (P/E) ratio for Crinetics Pharmaceuticals (CRNX) stock is 0 as of June 20, 2025.
Does Crinetics Pharmaceuticals stock pay dividends?
No, Crinetics Pharmaceuticals (CRNX) stock does not pay dividends to its shareholders as of June 20, 2025.
When is the next Crinetics Pharmaceuticals dividend payment date?
Crinetics Pharmaceuticals (CRNX) stock does not pay dividends to its shareholders.
What is the beta indicator for Crinetics Pharmaceuticals?
Crinetics Pharmaceuticals (CRNX) has a beta rating of 0.28. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.